Most importantly, our meta-analysis adds evidence to previous meta-analyses12,18,21, as it is the only one to incorporate the TSA approach, which allowed us to exclude a clinically relevant magnitude of the association between GLP-1 analogues and pancreatic cancer. The gene discussed is GLP1R; the disease is familial pancreatic carcinoma.